ACM Global Laboratories Appoints Brian Wright as President
Rochester Regional Health (RRH), a $2.2 USD billion integrated health care delivery system with more than 17,000 employees, has announced that its wholly-owned subsidiary, ACM Global Laboratories, has hired Brian Wright to lead ACM Global.
“Brian Wright was the clear choice to lead ACM Global today and into the future,” stated Eric Bieber, MD, president and CEO of ACM’s parent company, Rochester Regional Health. “Brian is an innovative, transformative leader who brings the expertise and passion for excellence that will build on the success of the rapidly growing ACM Global portfolio.”
Wright is a performance-driven, seasoned executive with more than 15 years of leadership experience in life science, biotech, medical and pharmaceutical technology and device manufacturing for global companies including Stryker Corporation, TE Connectivity and SP Industries. He has extensive training and expertise in Lean Six Sigma methodologies, process improvement management, and integrated supply chain management, as well as change management, leadership and communication. Wright, a decorated veteran of the U.S. Army, held the rank of Captain and was awarded the Combat Action Badge during his time of honorable service.
“Partnering with leading scientists and researchers across the globe, ACM Global helps bring new medicines to market to fight disease and provide health, healing and hope to millions through smarter testing,” stated Wright. “I am thrilled to be joining ACM Global at such an exciting time.”
Headquartered in the U.S., ACM Global is one of the largest global independent laboratories in the industry, performing more than 30 million laboratory tests annually and employing scientists and support personnel in the Americas, Europe, Singapore, China and India.
ACM Global has grown significantly over its 40-year history, both organically and through acquisitions, adding to its collection of domestic and international laboratories focused on bioanalytical, toxicology and central lab testing. In late 2017, ACM added Philadelphia-based DrugScan, Inc. and DSI Medical Services, Inc. to their portfolio. In 2018, ACM Global added Welwyn, England-based ABS Laboratories to expand their portfolio of complex assay method development and validation for the quantification of drugs, metabolites and biomarkers in biological samples for preclinical and clinical trials including final regulatory submission.
About Rochester Regional Health
Rochester Regional Health is an integrated health services organization serving the people of Western New York, the Finger Lakes and beyond. The system includes five hospitals; primary and specialty practices, rehabilitation centers, ambulatory campuses and immediate care facilities; innovative senior services, facilities and independent housing; a wide range of behavioral health services; and Rochester Regional Health Laboratories and ACM Global Laboratories, a global leader in patient and clinical trials. Rochester Regional Health is the region’s second largest employer. Learn more at RochesterRegional.org.
About ACM Global Laboratories
ACM Global Laboratories, an affiliate of Rochester Regional Health, is one of the largest global independent central labs in the industry. ACM is certified by the College of American Pathologists (CAP) and the Substance Abuse and Mental Health Services Administration (SAMHSA). The company delivers high-quality laboratory testing and diagnostic lab services in support of both clinical trials research, toxicology and individual patient care. ACM provides a powerful combination of operational excellence, scientific expertise and unsurpassed global service to customers in more than 65 countries. ACM performs more than 30 million laboratory tests each year—spanning all medical disciplines including pathology, microbiology, molecular diagnostics, toxicology and more. For more information, visit ACMGlobalLab.com or call +1-866-405-0400.
Rochester Regional Health
Veronica Chiesi Brown
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Defence Unlimited International Corp. is Hiring Veterans17.7.2019 20:58:00 CEST | Press release
Defence Unlimited International is one of the fastest growing companies operating within the defence and security space. Defence Unlimited International has adopted a unique outsourced model which integrates multiple partners both individual and corporate, on its projects. This has enabled it to offer and deliver to its clients best of breed bespoke solutions. Whilst Defence Unlimited is pursuing its drive towards achieving a more global footprint in its operations, the founder, Edward Banayoti firmly reiterates the continued commitment of the company to its existing strategy of identifying and successfully deploying experienced individuals that have served in the military. Individuals and teams with such experience can offer invaluable value added within projects Defence Unlimited are active in or are in the process of executing. "We take pride in our track record of offering numerous opportunities to Veterans who have served their country, giving such individuals who have heeded a pa
Temenos Acquires a SaaS-based, Patented, Explainable AI (XAI) Platform to Accelerate its AI Roadmap and Expertise17.7.2019 16:22:00 CEST | Press release
Contact information Media Contacts Jessica Wolfe Temenos Global Public Relations Tel: +1 610 232 2793 Email : email@example.com Alistair Kellie & Andrew Adie Newgate Communications on behalf of Temenos Tel: +44 20 7680 6550 Email: firstname.lastname@example.org
Gartner Names Airship a Leader, Positioned Highest in Execution and Furthest in Vision in the Magic Quadrant for Mobile Marketing Platforms17.7.2019 15:59:00 CEST | Press release
Customer engagement company Airship today announced that it has been named a Leader by Gartner, Inc. in its 2019 Magic Quadrant for Mobile Marketing Platforms1. Among 18 vendors evaluated, Airship was positioned highest in its ability to execute and also furthest for its completeness of vision. A complimentary copy of the full report is available from Airship. “We believe Gartner’s positioning of Airship validates our unique ability to deliver innovative, transformative digital customer experiences for the world’s leading brands,” said Brett Caine, CEO and president, Airship. “Airship delivers rich messages with pinpoint accuracy on whatever channel is most convenient and effective for the customer. Today’s customer expects proactive information and real-time response, and Airship is the essential component that makes it all possible.” According to Gartner, “Globally, consumers spend more of their time on smartphones than on desktops, laptops or tablets. This broad and rapid consumer a
GSMA Signs £38 Million Funding Partnership With the Department of International Development17.7.2019 15:02:00 CEST | Press release
The GSMA today announced that it has signed a thirty-eight million-pound partnership with the UK’s Department for International Development (DFID). The ‘Partnership for Inclusion, Innovation and Scale’ will provide funding for the GSMA’s Mobile for Development work on digital inclusion, digital identity, energy, water, sanitation and the reduction of the mobile gender gap. It will also include two new areas of focus: disability and climate. “This landmark partnership with DFID reinforces the joint power and potential of the private and public sectors working together and ensures that we will continue our crucial role of stimulating digital innovation to deliver both sustainable business and large-scale socio-economic impact for the underserved,” said Mats Granryd, Director General, GSMA. “This project reinforces our commitment to supporting the UN’s Sustainable Development Goals and using the power of technology to reduce global inequalities.” Inclusion, Innovation and Scale The partne
Gilead Sciences Announces Changes to Senior Leadership Team17.7.2019 12:30:00 CEST | Press release
Gilead Sciences, Inc. (Nasdaq: GILD) announced today changes to the company’s senior leadership team. Gregg Alton, Chief Patient Officer, and Katie Watson, Executive Vice President, Human Resources, will be departing Gilead. Jyoti Mehra has been named Executive Vice President, Human Resources, and will assume responsibility for the worldwide HR function. Mr. Alton joined Gilead in 1999 and most recently has led Gilead’s corporate and medical affairs functions and developing world access programs, as well as commercial operations in certain countries of Asia and Latin America. He previously served as general counsel and helped to architect the company’s innovative access model for HIV and viral hepatitis medicines in resource-limited countries. He will remain with Gilead through October 4 and plans to serve in an advisory capacity until the end of the year to help transition his responsibilities to other parts of the organization. “Gregg has been a valued leader at Gilead for nearly 20
Gilead Sciences’ Chief Scientific Officer John McHutchison to Leave the Company17.7.2019 12:30:00 CEST | Press release
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that John McHutchison, AO, MD, Chief Scientific Officer and Head of Research & Development, has decided to leave the company, effective next month. The company will immediately commence a search for his successor. Dr. McHutchison joined Gilead in 2010 and under his leadership, Gilead has developed five medicines that have been used by more than 3.2 million people around the world for the curative treatment of chronic hepatitis C, and treatment of chronic hepatitis B. He also oversaw the company’s expansion into oncology with the development of Gilead’s first cancer medicine, Zydelig® (idelalisib). He was appointed Chief Scientific Officer in March 2018. During his tenure, he has been responsible for broadening and overseeing the company’s Research and Development pipeline, advancing candidates in new therapeutic areas, including oncology, cell therapy and inflammation. “Over the past nine years, John’s scientific contributions and le